Eltrombopag

證據等級: L5

預測適應症: 1 個

Eltrombopag: From Thrombocytopenia (ITP) to HIV Infectious Disease

One-Sentence Summary

Eltrombopag is a thrombopoietin receptor agonist (TPO-RA), approved internationally for the treatment of immune thrombocytopenia (ITP) and aplastic anaemia, though not currently registered in New Zealand or Taiwan. The TxGNN model predicts it may be effective for HIV Infectious Disease — primarily targeting HIV-associated thrombocytopenia (HIV-ITP), with exploratory evidence also suggesting potential direct antiviral activity. Currently 5 clinical trials and 10 publications support this direction.

Quick Overview

Item	Content
Original Indication	Immune Thrombocytopenia (ITP) / Thrombocytopenia (not registered in New Zealand)
Predicted New Indication	HIV Infectious Disease
TxGNN Prediction Score	99.26%
Evidence Level	L2
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

The prediction is mechanistically supported by at least two distinct pathways. HIV infection causes thrombocytopenia (HIV-ITP) in approximately 30–40% of infected individuals, via immune-mediated platelet destruction and bone marrow suppression. As a TPO receptor agonist, eltrombopag stimulates the c-Mpl receptor on megakaryocytes to promote platelet production, directly addressing this common and clinically significant HIV complication. Multiple case reports and a case series (PMID 25504472, 22992580, 25333665) confirm its use as salvage therapy in HIV-ITP patients who have failed standard treatment including HAART optimisation.

A second mechanistic angle emerges from a 2020 high-throughput screen of FDA-approved drugs (PMID 32977702), which identified eltrombopag as a modulator of HIV-1 proviral transcription — suggesting potential direct antiviral activity beyond its haematological effects. Additionally, eltrombopag's known iron-chelating properties may suppress HIV replication by inhibiting iron-dependent viral enzymes. These converging mechanisms provide plausible biological grounding for the TxGNN model's prediction.

It should be noted that the primary and better-evidenced repurposing rationale is for HIV-associated haematological complications (ITP, aplastic anaemia), not direct antiviral therapy. The direct antiviral pathway remains at an exploratory, mechanistic stage and would require dedicated clinical investigation before any therapeutic claim can be made.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01636778	Phase 2	Completed	45	SB-497115 (eltrombopag development code) in thrombocytopenic HCV/cirrhosis patients; non-randomised open-label design; most representative prospective dataset applicable to HIV-ITP, assessing ability to raise and maintain platelet counts to enable antiviral therapy initiation
NCT00529568	Phase 3	Completed	759	Randomised, placebo-controlled; eltrombopag in HCV-ITP patients initiating Peg-IFN alfa-2b + ribavirin; primary endpoint sustained virological response (SVR); large-scale trial providing strong indirect support for infection-related ITP management
NCT00516321	Phase 3	Completed	687	Randomised, placebo-controlled; parallel design to NCT00529568 using Peg-IFN alfa-2a; confirms platelet maintenance benefit enabling antiviral therapy completion; supports general infection-related ITP evidence base
NCT00996216	Phase 3	Completed	27	Open-label rollover study; long-term safety and tolerability of eltrombopag in HCV-ITP; very small sample (N=27) limits efficacy conclusions but contributes extended safety data
NCT00678587	Phase 3	Terminated	292	Eltrombopag to reduce platelet transfusion need in chronic liver disease with thrombocytopenia; terminated early (only partial enrolment achieved); reason undisclosed — potential safety or futility signal; treat as a risk indicator rather than positive evidence

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25504472	2015	Case Series / Cohort	J Int Assoc Providers AIDS Care	First reported experience with TPO-RA (eltrombopag and romiplostim) in refractory HIV-ITP; eltrombopag effective as salvage therapy following failure of HAART optimisation and standard ITP treatment
22992580	2012	Case Report	AIDS	Successful eltrombopag use without splenectomy in refractory HIV-related immune reconstitution thrombocytopenia; demonstrates feasibility in the specific HIV immune reconstitution context
25333665	2014	Case Report	AIDS	First report of eltrombopag for HIV-associated aplastic anaemia; trilineage haematological response observed; immunomodulatory effects documented (↓Th1/Th17, ↑Treg ratio), suggesting mechanisms beyond TPO stimulation
32977702	2020	Mechanistic Screen	Viruses	High-throughput screen of FDA-approved drugs identifies eltrombopag as a modulator of HIV-1 proviral transcription; provides mechanistic rationale for potential direct antiviral repurposing beyond haematological indication
22185370	2012	Cohort (Registry)	Platelets	Danish real-world registry of TPO-RA use including off-label applications in secondary ITP (HIV, chronic lymphatic leukaemia); supports broader infection-related ITP use pattern
24816314	2014	Cohort	Internal Medicine Journal	TPO receptor agonist use in ITP of <6 months duration including secondary ITP subgroups; includes clinical experience relevant to HIV-ITP
19245929	2009	Review	Seminars in Hematology	Therapeutic strategies for HCV- and HIV-related immune thrombocytopenias; contextualises the role of TPO-RA in secondary ITP management
19932434	2009	Review	Hematol Oncol Clin North Am	Infectious causes of chronic ITP (HCV, HIV, H. pylori); treating the primary infection often improves thrombocytopenia; eltrombopag cited as adjunct option in refractory cases
24128106	2013	Case Report	Farmacia Hospitalaria	Two cases of eltrombopag for chronic hepatitis C-related thrombocytopenia; indirect support for infection-associated ITP management
28043314	2016	Case Report	J Coll Physicians Surg Pak	Hepatitis B-associated megaloblastic anaemia and severe thrombocytopenia; illustrates complexity of infection-related thrombocytopenia differential diagnosis

New Zealand Market Information

Eltrombopag is not currently registered or authorised for use in New Zealand. No Medsafe authorisations were found in the database query conducted on 2026-03-29.

Safety Considerations

Please refer to the package insert for safety information.

Note: Safety data (key warnings, contraindications, drug-drug interactions) were not retrievable in this evidence pack. Given that HIV patients typically receive multiple antiretrovirals and co-medications, a dedicated DDI review against common HAART regimens is strongly recommended before any clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 3 trials in infection-related ITP and direct HIV-ITP case evidence collectively support eltrombopag's haematological efficacy at L2 level; an additional mechanistic study raises the prospect of direct antiviral activity. However, the drug is not registered in New Zealand/Taiwan, safety data were not captured in this pack, and HIV-specific prospective RCT evidence is absent.

To proceed, the following is needed:

Retrieve and review the full prescribing information (package insert) for key warnings and contraindications — especially hepatotoxicity risk, which is a known concern for eltrombopag and particularly relevant in HIV patients with potential co-existing liver disease
Conduct a formal drug-drug interaction review against common HAART regimens (e.g. protease inhibitors, NNRTIs) and relevant co-medications
Obtain complete MOA data from DrugBank to formalise the mechanistic link analysis
Commission or identify a dedicated prospective cohort study or RCT in HIV-ITP patients; current evidence is primarily extrapolated from HCV-ITP trials and small case series
Assess the regulatory pathway for New Zealand/Taiwan market authorisation, including whether data packages from existing international approvals (e.g. FDA, EMA) are sufficient to support a local filing
Define a safety monitoring plan covering complete blood count, liver function tests, and thromboembolic event surveillance for any pilot use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.